The role of BH3-only proteins in tumor cell development, signaling, and treatment

Genes and Cancer

Volumn 2, Issue 5, 2011, Pages 523-537

  Elkholi, Rana ^a   Floros, Konstantinos V ^a   Chipuk, Jerry E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; BCL 2 family; BH3 only proteins; cancer; mitochondria

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; APOGOSSYPOL; APOPTOSIS INHIBITOR; BCL 2 MODIFYING FACTOR; BH3 PROTEIN; BIM PROTEIN; GOSSYPOL; GOSSYPOL DERIVATIVE; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; OUTER MEMBRANE PROTEIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN INHIBITOR; PROTEIN NOXA; PUMA PROTEIN; TM 106; TW 37; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ENZYME ACTIVITY; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALE INFERTILITY; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

EID: 80053018164     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911417177     Document Type: Review

References (130)

1. Barr PJ,Tomei LD.Apoptosis and its role in human disease.Biotechnology (N Y). 1994;12:487-93.
2. McDonnell TJ,Korsmeyer SJ.Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18).Nature. 1991;349:254-6.
3. Strasser A,Whittingham S,Vaux DL, et al.Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.Proc Natl Acad Sci U S A. 1991;88:8661-5.
4. Thompson CB.Apoptosis in the pathogenesis and treatment of disease.Science. 1995;267:1456-62.
5. Watanabe-Fukunaga R,Brannan CI,Copeland NG,Jenkins NA,Nagata S.Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.Nature. 1992;356:314-7.
6. Guicciardi ME,Gores GJ.Life and death by death receptors.FASEB J. 2009;23:1625-37.
7. Chipuk JE,Green DR.How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?.Trends Cell Biol. 2008;18:157-64.
8. Pop C,Salvesen GS.Human caspases: activation, specificity, and regulation.J Biol Chem. 2009;284:21777-81.
9. Chipuk JE,Moldoveanu T,Llambi F,Parsons MJ,Green DR.The BCL-2 family reunion.Mol Cell. 2010;37:299-310.
10. Petros AM,Olejniczak ET,Fesik SW.Structural biology of the Bcl-2 family of proteins.Biochim Biophys Acta. 2004;1644:83-94.
11. Tsujimoto Y,Gorham J,Cossman J,Jaffe E,Croce CM.The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining.Science. 1985;229:1390-3.
12. Vaux DL,Cory S,Adams JM.Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.Nature. 1988;335:440-2.
13. Zhu W,Cowie A,Wasfy GW,Penn LZ,Leber B,Andrews DW.Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types.EMBO J. 1996;15:4130-41.
14. Kvansakul M,Yang H,Fairlie WD, et al.Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands.Cell Death Differ. 2008;15:1564-71.
15. Oltvai ZN,Milliman CL,Korsmeyer SJ.Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.Cell. 1993;74:609-19.
16. Chittenden T,Harrington EA,O'Connor R, et al.Induction of apoptosis by the Bcl-2 homologue Bak.Nature. 1995;374:733-6.
17. Moldoveanu T,Liu Q,Tocilj A,Watson M,Shore G,Gehring K.The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site.Mol Cell. 2006;24:677-88.
18. Kuwana T,Mackey MR,Perkins G, et al.Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane.Cell. 2002;111:331-42.
19. Lindsten T,Ross AJ,King A, et al.The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues.Mol Cell. 2000;6:1389-99.
20. Wei MC,Zong WX,Cheng EH, et al.Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death.Science. 2001;292:727-30.
21. Suzuki M,Youle RJ,Tjandra N.Structure of Bax: coregulation of dimer formation and intracellular localization.Cell. 2000;103:645-54.
22. Hinds MG,Smits C,Fredericks-Short R, et al.Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets.Cell Death Differ. 2007;14:128-36.
23. Wei MC,Lindsten T,Mootha VK, et al.tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c.Genes Dev. 2000;14:2060-71.
24. Kuwana T,Bouchier-Hayes L,Chipuk JE, et al.BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly.Mol Cell. 2005;17:525-35.
25. Letai A,Bassik MC,Walensky LD,Sorcinelli MD,Weiler S,Korsmeyer SJ.Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.Cancer Cell. 2002;2:183-92.
26. Chipuk JE,Green DR.PUMA cooperates with direct activator proteins to promote mitochondrial outer membrane permeabilization and apoptosis.Cell Cycle. 2009;8:2692-6.
27. Ren D,Tu HC,Kim H, et al.BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program.Science. 2010;330:1390-3.
28. Willis SN,Fletcher JI,Kaufmann T, et al.Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.Science. 2007;315:856-9.
29. Inohara N,Ding L,Chen S,Nunez G.harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L).EMBO J. 1997;16:1686-94.
30. Nakano K,Vousden KH.PUMA, a novel proapoptotic gene, is induced by p53.Mol Cell. 2001;7:683-94.
31. Oda E,Ohki R,Murasawa H, et al.Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.Science. 2000;288:1053-8.
32. Puthalakath H,Villunger A,O'Reilly LA, et al.Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis.Science. 2001;293:1829-32.
33. Yang E,Zha J,Jockel J,Boise LH,Thompson CB,Korsmeyer SJ.Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death.Cell. 1995;80:285-91.
34. Dewson G,Kratina T,Czabotar P,Day CL,Adams JM,Kluck RM.Bak activation for apoptosis involves oligomerization of dimers via their alpha6 helices.Mol Cell. 2009;36:696-703.
35. Wolter KG,Hsu YT,Smith CL,Nechushtan A,Xi XG,Youle RJ.Movement of Bax from the cytosol to mitochondria during apoptosis.J Cell Biol. 1997;139:1281-92.
36. Karbowski M,Norris KL,Cleland MM,Jeong SY,Youle RJ.Role of Bax and Bak in mitochondrial morphogenesis.Nature. 2006;443:658-62.
37. Edlich F,Banerjee S,Suzuki M, et al.Bcl-x(L) Retrotranslocates Bax from the mitochondria into the cytosol.Cell. 2011;145:104-16.
38. Gavathiotis E,Reyna DE,Davis ML,Bird GH,Walensky LD.BH3-triggered structural reorganization drives the activation of proapoptotic BAX.Mol Cell. 2010;40:481-92.
39. Kim H,Tu HC,Ren D, et al.Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis.Mol Cell. 2009;36:487-99.
40. Lovell JF,Billen LP,Bindner S, et al.Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax.Cell. 2008;135:1074-84.
41. Danial NN.BAD: undertaker by night, candyman by day.Oncogene. 2008;27 (Suppl 1): S53-70.
42. Datta SR,Katsov A,Hu L, et al.14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation.Mol Cell. 2000;6:41-51.
43. del Peso L,Gonzalez-Garcia M,Page C,Herrera R,Nunez G.Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.Science. 1997;278:687-9.
44. Donovan N,Becker EB,Konishi Y,Bonni A.JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery.J Biol Chem. 2002;277:40944-9.
45. Zha J,Harada H,Yang E,Jockel J,Korsmeyer SJ.Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L).Cell. 1996;87:619-28.
46. Zha J,Harada H,Osipov K,Jockel J,Waksman G,Korsmeyer SJ.BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity.J Biol Chem. 1997;272:24101-4.
47. Danial NN,Gramm CF,Scorrano L, et al.BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis.Nature. 2003;424:952-6.
48. Danial NN,Walensky LD,Zhang CY, et al.Dual role of proapoptotic BAD in insulin secretion and beta cell survival.Nat Med. 2008;14:144-53.
49. Ranger AM,Zha J,Harada H, et al.Bad-deficient mice develop diffuse large B cell lymphoma.Proc Natl Acad Sci U S A. 2003;100:9324-9.
50. Blume-Jensen P,Janknecht R,Hunter T.The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136.Curr Biol. 1998;8:779-82.
51. She QB,Solit DB,Ye Q,O'Reilly KE,Lobo J,Rosen N.The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.Cancer Cell. 2005;8:287-97.
52. Oh KJ,Barbuto S,Meyer N,Kim RS,Collier RJ,Korsmeyer SJ.Conformational changes in BID, a pro-apoptotic BCL-2 family member, upon membrane binding: a site-directed spin labeling study.J Biol Chem. 2005;280:753-67.
53. Zha J,Weiler S,Oh KJ,Wei MC,Korsmeyer SJ.Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis.Science. 2000;290:1761-5.
54. Leber B,Lin J,Andrews DW.Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes.Apoptosis. 2007;12:897-911.
55. McDonnell JM,Fushman D,Milliman CL,Korsmeyer SJ,Cowburn D.Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists.Cell. 1999;96:625-34.
56. Grinberg M,Sarig R,Zaltsman Y, et al.tBID Homooligomerizes in the mitochondrial membrane to induce apoptosis.J Biol Chem. 2002;277:12237-45.
57. Billen LP,Shamas-Din A,Andrews DW.Bid: a Bax-like BH3 protein.Oncogene. 2008;27 (Suppl 1): S93-104.
58. Desagher S,Osen-Sand A,Montessuit S, et al.Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8.Mol Cell. 2001;8:601-11.
59. Upton JP,Austgen K,Nishino M, et al.Caspase-2 cleavage of BID is a critical apoptotic signal downstream of endoplasmic reticulum stress.Mol Cell Biol. 2008;28:3943-51.
60. Bonzon C,Bouchier-Hayes L,Pagliari LJ,Green DR,Newmeyer DD.Caspase-2-induced apoptosis requires bid cleavage: a physiological role for bid in heat shock-induced death.Mol Biol Cell. 2006;17:2150-7.
61. Kamer I,Sarig R,Zaltsman Y, et al.Proapoptotic BID is an ATM effector in the DNA-damage response.Cell. 2005;122:593-603.
62. Baptiste-Okoh N,Barsotti AM,Prives C.A role for caspase 2 and PIDD in the process of p53-mediated apoptosis.Proc Natl Acad Sci U S A. 2008;105:1937-42.
63. Tinel A,Tschopp J.The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress.Science. 2004;304:843-6.
64. Kaufmann T,Tai L,Ekert PG, et al.The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest.Cell. 2007;129:423-33.
65. Zinkel SS,Ong CC,Ferguson DO, et al.Proapoptotic BID is required for myeloid homeostasis and tumor suppression.Genes Dev. 2003;17:229-39.
66. Zinkel SS,Hurov KE,Ong C,Abtahi FM,Gross A,Korsmeyer SJ.A role for proapoptotic BID in the DNA-damage response.Cell. 2005;122:579-91.
67. Yeretssian G,Correa RG,Doiron K, et al.Non-apoptotic role of BID in inflammation and innate immunity.Nature. 2011;474:96-9.
68. O'Connor L,Strasser A,O'Reilly LA, et al.Bim: a novel member of the Bcl-2 family that promotes apoptosis.EMBO J. 1998;17:384-95.
69. Dijkers PF,Medema RH,Lammers JW,Koenderman L,Coffer PJ.Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1.Curr Biol. 2000;10:1201-4.
70. Yang JY,Chang CJ,Xia W, et al.Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.Cancer Res. 2010;70:4709-18.
71. Puthalakath H,O'Reilly LA,Gunn P, et al.ER stress triggers apoptosis by activating BH3-only protein Bim.Cell. 2007;129:1337-49.
72. Lei K,Davis RJ.JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis.Proc Natl Acad Sci U S A. 2003;100:2432-7.
73. Cragg MS,Jansen ES,Cook M,Harris C,Strasser A,Scott CL.Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.J Clin Invest. 2008;118:3651-9.
74. Cragg MS,Kuroda J,Puthalakath H,Huang DC,Strasser A.Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.PLoS Med. 2007;4:1681-89.
75. Deng J,Shimamura T,Perera S, et al.Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.Cancer Res. 2007;67:11867-75.
76. Sinicrope FA,Rego RL,Okumura K, et al.Prognostic impact of bim, puma, and noxa expression in human colon carcinomas.Clin Cancer Res. 2008;14:5810-8.
77. Mestre-Escorihuela C,Rubio-Moscardo F,Richter JA, et al.Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.Blood. 2007;109:271-80.
78. Bouillet P,Metcalf D,Huang DC, et al.Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity.Science. 1999;286:1735-8.
79. Egle A,Harris AW,Bouillet P,Cory S.Bim is a suppressor of Myc-induced mouse B cell leukemia.Proc Natl Acad Sci U S A. 2004;101:6164-9.
80. Vaux DL,Adams JM,Alexander WS,Pike BL.Immunologic competence of B cells subjected to constitutive c-myc oncogene expression in immunoglobulin heavy chain enhancer myc transgenic mice.J Immunol. 1987;139:3854-60.
81. Tan TT,Degenhardt K,Nelson DA, et al.Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.Cancer Cell. 2005;7:227-38.
82. Schmelzle T,Mailleux AA,Overholtzer M, et al.Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis.Proc Natl Acad Sci U S A. 2007;104:3787-92.
83. Frenzel A,Labi V,Chmelewskij W, et al.Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad.Blood. 2010;115:995-1005.
84. Han J,Flemington C,Houghton AB, et al.Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals.Proc Natl Acad Sci U S A. 2001;98:11318-23.
85. Kaeser MD,Iggo RD.Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo.Proc Natl Acad Sci U S A. 2002;99:95-100.
86. Futami T,Miyagishi M,Taira K.Identification of a network involved in thapsigargin-induced apoptosis using a library of small interfering RNA expression vectors.J Biol Chem. 2005;280:826-31.
87. Li J,Lee B,Lee AS.Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53.J Biol Chem. 2006;281:7260-70.
88. You H,Pellegrini M,Tsuchihara K, et al.FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal.J Exp Med. 2006;203:1657-63.
89. Wu WS,Heinrichs S,Xu D, et al.Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma.Cell. 2005;123:641-53.
90. Fricker M,O'Prey J,Tolkovsky AM,Ryan KM.Phosphorylation of Puma modulates its apoptotic function by regulating protein stability.Cell Death Dis. 2010;1:e59.
91. Jabbour AM,Heraud JE,Daunt CP, et al.Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim.Cell Death Differ. 2009;16:555-63.
92. Chipuk JE,Fisher JC,Dillon CP,Kriwacki RW,Kuwana T,Green DR.Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins.Proc Natl Acad Sci U S A. 2008;105:20327-32.
93. Chipuk JE,Bouchier-Hayes L,Kuwana T,Newmeyer DD,Green DR.PUMA couples the nuclear and cytoplasmic proapoptotic function of p53.Science. 2005;309:1732-5.
94. Jeffers JR,Parganas E,Lee Y, et al.Puma is an essential mediator of p53-dependent and -independent apoptotic pathways.Cancer Cell. 2003;4:321-8.
95. Hemann MT,Zilfou JT,Zhao Z,Burgess DJ,Hannon GJ,Lowe SW.Suppression of tumorigenesis by the p53 target PUMA.Proc Natl Acad Sci U S A. 2004;101:9333-8.
96. Erlacher M,Labi V,Manzl C, et al.Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction.J Exp Med. 2006;203:2939-51.
97. Wang YF,Jiang CC,Kiejda KA,Gillespie S,Zhang XD,Hersey P.Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.Clin Cancer Res. 2007;13:4934-42.
98. Wang X,Li M,Wang J, et al.The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells.Biochem Pharmacol. 2006;71:1540-50.
99. Wang P,Yu J,Zhang L.The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage.Proc Natl Acad Sci U S A. 2007;104:4054-9.
100. Hijikata M,Kato N,Sato T,Kagami Y,Shimotohno K.Molecular cloning and characterization of a cDNA for a novel phorbol-12-myristate-13-acetate-responsive gene that is highly expressed in an adult T-cell leukemia cell line.J Virol. 1990;64:4632-9.
101. Kim JY,Ahn HJ,Ryu JH,Suk K,Park JH.BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha.J Exp Med. 2004;199:113-24.
102. Shibue T,Takeda K,Oda E, et al.Integral role of Noxa in p53-mediated apoptotic response.Genes Dev. 2003;17:2233-8.
103. Villunger A,Michalak EM,Coultas L, et al.p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa.Science. 2003;302:1036-8.
104. Michalak EM,Jansen ES,Happo L, et al.Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis.Cell Death Differ. 2009;16:684-96.
105. Olejniczak ET,Van Sant C,Anderson MG, et al.Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.Mol Cancer Res. 2007;5:331-9.
106. Klasa RJ,Gillum AM,Klem RE,Frankel SR.Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.Antisense Nucleic Acid Drug Dev. 2002;12:193-213.
107. Jansen B,Schlagbauer-Wadl H,Brown BD, et al.bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice.Nat Med. 1998;4:232-4.
108. Wang JL,Liu D,Zhang ZJ, et al.Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells.Proc Natl Acad Sci U S A. 2000;97:7124-9.
109. Lickliter JD,Wood NJ,Johnson L, et al.HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death.Leukemia. 2003;17:2074-80.
110. Manero F,Gautier F,Gallenne T, et al.The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death.Cancer Res. 2006;66:2757-64.
111. Nguyen M,Marcellus RC,Roulston A, et al.Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.Proc Natl Acad Sci U S A. 2007;104:19512-7.
112. Parikh SA,Kantarjian H,Schimmer A, et al.Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.Clin Lymphoma Myeloma Leuk. 2010;10:285-9.
113. Schimmer AD,O'Brien S,Kantarjian H, et al.A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.Clin Cancer Res. 2008;14:8295-301.
114. Konopleva M,Watt J,Contractor R, et al.Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).Cancer Res. 2008;68:3413-20.
115. Mott JL,Bronk SF,Mesa RA,Kaufmann SH,Gores GJ.BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis.Mol Cancer Ther. 2008;7:2339-47.
116. Benz CC,Keniry MA,Ford JM, et al.Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers.Mol Pharmacol. 1990;37:840-7.
117. Kitada S,Kress CL,Krajewska M,Jia L,Pellecchia M,Reed JC.Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048).Blood. 2008;111:3211-9.
118. Sun J,Li ZM,Hu ZY, et al.ApoG2 inhibits antiapoptotic Bcl-2 family proteins and induces mitochondria-dependent apoptosis in human lymphoma U937 cells.Anticancer Drugs. 2008;19:967-74.
119. Sun Y,Wu J,Aboukameel A, et al.Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.Cancer Biol Ther. 2008;7:1418-26.
120. Al-Katib AM,Sun Y,Goustin AS, et al.SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status.J Hematol Oncol. 2009;2:8.
121. Walensky LD,Kung AL,Escher I, et al.Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.Science. 2004;305:1466-70.
122. Stewart ML,Fire E,Keating AE,Walensky LD.The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer.Nat Chem Biol. 2010;6:595-601.
123. Oltersdorf T,Elmore SW,Shoemaker AR, et al.An inhibitor of Bcl-2 family proteins induces regression of solid tumours.Nature. 2005;435:677-81.
124. van Delft MF,Wei AH,Mason KD, et al.The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.Cancer Cell. 2006;10:389-99.
125. Mason KD,Carpinelli MR,Fletcher JI, et al.Programmed anuclear cell death delimits platelet life span.Cell. 2007;128:1173-86.
126. Tse C,Shoemaker AR,Adickes J, et al.ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.Cancer Res. 2008;68:3421-8.
127. Wang G,Nikolovska-Coleska Z,Yang CY, et al.Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.J Med Chem. 2006;49:6139-42.
128. Kitada S,Leone M,Sareth S,Zhai D,Reed JC,Pellecchia M.Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins.J Med Chem. 2003;46:4259-64.
129. Bruncko M,Oost TK,Belli BA, et al.Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.J Med Chem. 2007;50:641-62.
130. Zhai D,Jin C,Satterthwait AC,Reed JC.Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins.Cell Death Differ. 2006;13:1419-21.